IMAB I-Mab Inc. Earnings per share for the last twelve months

IMAB (I-Mab Biopharma Co., Ltd.) - company brandmark

While adhering to environmental regulations for bio-waste disposal, I-Mab focuses on antibody development. The TTM earnings per share trend helps identify hidden overheating or growth potential, with the metric currently recorded at -0.71. Development relies on the automation of R&D centers under the supervision of scientists, while business resilience is ensured by the distribution of research hubs between the US and China.

IMAB (I-Mab) Net earnings per share for the last 12 months history from 07/04/2022 to 10/30/2025

I-Mab Biopharma Co., Ltd. - analytical breakdowns and key metrics (IMAB)

- current quotes and average value forecast:
Price Chart I-Mab Inc.|IMAB - Average Forecast Price
- market capitalization data:
Market Value I-Mab Biopharma|IMAB - Business Value
- shareholders' equity book value data:
Book Value per Share I-Mab|IMAB - Company Net Assets|Market Value to Book Value Ratio i-mabbiopharma.com|IMAB - Company Assets
- debt burden and liquidity indicators:
Debt to Equity I-Mab|IMAB - Long-Term Debt to Equity|Short-Term Debt to Equity I-Mab Inc.|IMAB - Company Cumulative Debt|Debts to Book Capitalization I-Mab Biopharma|IMAB - Long-Term Indebtedness|Company Current Liabilities I-Mab|Quick Liquidity Indicator i-mabbiopharma.com
- net income and valuation multiples indicators:
IMAB - Final Profit|Future Profit I-Mab|IMAB - Market Price to Net Income Ratio|Forward P/E Multiple I-Mab Inc.|IMAB - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple I-Mab Biopharma|IMAB - Profit before interest, taxes and amortization|Earnings per share for the last twelve months I-Mab|IMAB - Earnings per share for the trailing year|Quarterly EPS earnings growth i-mabbiopharma.com|IMAB - Earnings growth in current year|Net earnings per share growth forecast for next year I-Mab
Basic company analysis:i-mabbiopharma.com (IMAB)
Mass-produced product of I-Mab Inc.

This metric is calculated as the ratio of total net income over the last four quarters to the total number of common shares, measuring the actual return on each share of capital. Amid the restructuring of I-Mab (IMAB) and the creation of an immuno-oncology platform, the rolling earnings per share trend allows for an assessment of how effectively innovative antibodies convert into financial results, separating fundamental growth from market optimism.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months hutch-med.com|Nuvation Bio (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (Monopar Pharma) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Inhibrx Corp (INBX)|Earnings per share for the last twelve months Fennec Pharmaceuticals (FENC)|HRTX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Nuvectis Pharma NVCT|Coherus - Earnings per share for the last twelve months|CRBP - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Cardiff Oncology, Inc.|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharma CTXR|Net earnings per share for the last 12 months CLRB (Cellectar)|BLRX (BioLineRx Corporation) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea Therapeutics Inc.)|Kazia - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (Silexion Therapeutics Corp)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Chimerix Inc (CMRX)|Earnings per share for the last twelve months Cyclacel Pharmaceuticals|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Therapeutics Inc (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech Corp) - Earnings per one share for the last 12 months